Clusterstock  Jul 5  Comment 
Regeneron's CEO, Leonard Schleifer, once criticized arbitrary drug price increases by pharmaceutical companies. But in July, the company's eczema drug price increased by 3%. Regeneron said Sanofi had final decision-making authority on pricing...
Yahoo  Jul 3  Comment 
Sanofi (SASY.PA) sees a more diversified pipeline driving a return to growth at its diabetes unit in the coming years and will consider acquisitions and partnerships to help boost performance, a company executive said on Tuesday. The French...
FierceBiotech  Jun 29  Comment 
Four months after Voyager Therapeutics’ chief and founder Steven Paul, M.D., said he would step down to become an “executive science adviser,” the neurological disease biotech has found a new leader.
FiercePharma  Jun 28  Comment 
It’s official: Sanofi is finally ready to unload its European generics business. More than two months after disclosing that they were in exclusive talks, the French drugmaker and buyer Advent International have ironed out the details on a €1.9...
FiercePharma  Jun 22  Comment 
When the U.K.'s cost effectiveness watchdogs at NICE reviewed Sanofi's blockbuster hopeful Dupixent earlier this year, they concluded that the drug was an advance for atopic dermatitis patients, but too expensive to justify for coverage. Now,...
Channel News Asia  Jun 20  Comment 
Sanofi missed the boat on immune system-boosting cancer drugs. Now it's trying to catch up.
Yahoo  Jun 19  Comment 
Building up an investment case requires looking at a stock holistically. Today I’ve chosen to put the spotlight on Sanofi (ENXTPA:SAN) due to its excellent fundamentals in more than oneRead More...

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki